Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 7/20 | 0.65 |
| ▸ | PSMB5 | P28074 | 7/20 | 0.65 |
| ▸ | PSMB2 | P49721 | 6/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.63 |
| ▸ | LTA4H | P09960 | 9/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5114639 | 1.00 | PSMB1 (0.65) | PSMB1PSMB5PSMB2HRH3LTA4H | |
| SCHEMBL159557 | 0.98 | PSMB1 (0.62) | PSMB1PSMB5PSMB2HRH3LTA4H | |
| Hydrochloric Acid SCHEMBL7819689 | 0.96 | PSMB1 (0.60) | PSMB1PSMB5PSMB2HRH3LTA4H | |
| SCHEMBL2180987 | 0.91 | HRH3 (0.70) | HRH3 | |
| SCHEMBL3165031 | 0.89 | HRH3 (0.67) | HRH3KDM4E | |
| SCHEMBL3144386 | 0.88 | HRH3 (0.71) | PSMB1PSMB5PSMB2HRH3LTA4H | |
| SCHEMBL183199 | 0.84 | LTA4H (0.59) | HRH3LTA4HKDM4E | |
| SCHEMBL182574 | 0.83 | HRH3 (0.69) | PSMB1PSMB5PSMB2HRH3LTA4H | |
| SCHEMBL188972 | 0.83 | LTA4H (0.60) | PSMB1PSMB5PSMB2HRH3LTA4H | |
| SCHEMBL182770 | 0.83 | ALDH1A1 (0.57) | LTA4HKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3740493-B1 | INHIBTEURS DE L'INDOLEAMINE 2,3-DIOXYGÉNASE ET/OU DU TRYPTOPHANE DIOXYGÉNASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-12-01 | — | — | EP | claimed |
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-31 | — | — | US | claimed |
| EP-3740493-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | Idorsia Pharmaceuticals Ltd (CH) | 2020-11-25 | — | — | EP | claimed |
| CN-111601810-A | Inhibitors of indoleamine 2, 3-dioxygenase and/or tryptophan 2, 3-dioxygenase | 爱杜西亚药品有限公司 | 2020-08-28 | — | — | CN | claimed |
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-07 | — | — | US | claimed |
| US-7776867-B2 | Furanopyrimidines | AMGEN INC. (US) | 2010-08-17 | — | — | US | claimed |
| US-7674907-B2 | Furanopyridine derivatives and methods of use | AMGEN INC. (US) | 2010-03-09 | — | — | US | claimed |
| WO-2010014798-A2 | PYRIMIDOTRIAZINEDIONES AND PYRIMIDOPYRIMIDINEDIONES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-02-04 | — | — | WO | claimed |
| US-7452914-B2 | Spiro-benzo[c]chromene derivatives useful as modulators of the estrogen receptors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-18 | — | — | US | claimed |
| US-7329654-B2 | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-12 | — | — | US | claimed |
| EP-1467998-A1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-10-20 | — | — | EP | claimed |
| EP-1427421-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | Amgen Inc. (US) | 2004-06-16 | — | — | EP | claimed |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-04-29 | — | — | US | claimed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | claimed |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-20 | — | — | US | claimed |
| WO-2003075921-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | TRANSTECH PHARMA, INC. (US) | 2003-09-18 | — | — | WO | claimed |
| WO-2003053977-A1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-07-03 | — | — | WO | claimed |
| WO-2003018021-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | AMGEN INC. (US) | 2003-03-06 | — | — | WO | claimed |
| US-5731342-A | FOR TREATING AND PREVENTING POSTMENOPAUSAL SYNDROME AND BREAST CANCER | ELI LILLY AND COMPANY (US) | 1998-03-24 | — | — | US | claimed |
| US-3978055-A | SEDATIVE, ANTIINFLAMMATORY, VASODILATION, BRONCHODILATION | DELALANDE S.A. (FR) | 1976-08-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | PSMB1 3951/4885PSMB5 3165/4885PSMB2 4205/4885 |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | DPYD, TYMP, TPMT | PSMB1 4858/4885PSMB5 3726/4885PSMB2 4729/4885 |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | GPER1, ESR2, FSHR | PSMB1 1278/4885PSMB5 833/4885PSMB2 1340/4885 |
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDO2, TDO2, IDO1 | PSMB1 3716/4885PSMB5 2939/4885PSMB2 2459/4885 |
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | DPYD, TYMP, DHFR | PSMB1 4752/4885PSMB5 3855/4885PSMB2 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.